NCT07906262
Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to Defined Target Populations
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Pain Freedom at 2 Hours Postdose
Timeframe: 2 hours after administration of study treatment
Freedom From the Most Bothersome Symptom at 2 Hours Postdose
Timeframe: 2 hours after administration of study treatment
Pain Relief at 2 Hours Postdose
Timeframe: 2 hours after administration of study treatment
Secondary (15)
Pain Freedom at 1 Hour Postdose
Pain Relief at 1 Hour Postdose
Return to Normal Function at 1 Hour Postdose
Return to Normal Function at 2 Hours Postdose
Sustained Pain Freedom From 2 to 24 Hours Postdose
Show 10 moreShow less
Sustained Pain Freedom From 2 to 48 Hours Postdose
Sustained Pain Relief From 2 to 24 Hours Postdose
Sustained Pain Relief From 2 to 48 Hours Postdose
Freedom From Nausea at 1 Hour Postdose
Freedom From Nausea at 2 Hours Postdose
Freedom From Photophobia at 1 Hour Postdose
Freedom From Photophobia at 2 Hours Postdose
Freedom From Phonophobia at 1 Hour Postdose
Freedom From Phonophobia at 2 Hours Postdose
Rescue Medication Use Within 24 Hours Postdose
Arms and interventions
Rimegepant 75 mg
Participants from the included randomized, double-blind, placebo-controlled clinical trials who were randomized to receive rimegepant 75 mg for the acute treatment of a moderate or severe migraine attack.
Placebo
Participants from the included randomized, double-blind, placebo-controlled clinical trials who were randomized to receive placebo for the acute treatment of a moderate or severe migraine attack.
Drugs: Rimegepant, Placebo
Sites
1 site in 1 country
- PfizerNew York, New York, United States